Improving inhaled gene therapy for lung diseases
Overcoming Immunological Barriers to Inhaled AAV Gene Therapy
['FUNDING_FELLOWSHIP'] · TULANE UNIVERSITY OF LOUISIANA · NIH-10998666
This study is looking at how to make inhaled gene therapy work better for lung conditions like Cystic Fibrosis and pulmonary arterial hypertension by understanding how the immune system reacts to the treatment, so we can find ways to improve its effectiveness for patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TULANE UNIVERSITY OF LOUISIANA (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-10998666 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of inhaled gene therapy for lung disorders by addressing immune responses that hinder treatment. It investigates how the immune system, particularly B and T cells, reacts to adeno-associated virus (AAV) vectors used in gene therapy. The study aims to understand the unique challenges posed by the lung's immune environment and to develop strategies to overcome these barriers, potentially leading to more successful long-term gene expression in patients with conditions like Cystic Fibrosis and pulmonary arterial hypertension.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from lung disorders such as Cystic Fibrosis, primary ciliary dyskinesia, or pulmonary arterial hypertension.
Not a fit: Patients with non-lung-related conditions or those who do not respond to inhaled therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective gene therapies for patients with serious lung diseases.
How similar studies have performed: While gene therapy has shown success in other areas, the specific approach of overcoming immune barriers in lung-directed AAV therapy is relatively novel and has not been extensively tested.
Where this research is happening
NEW ORLEANS, UNITED STATES
- TULANE UNIVERSITY OF LOUISIANA — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CLARK, ROBERT DAVID EDWARD — TULANE UNIVERSITY OF LOUISIANA
- Study coordinator: CLARK, ROBERT DAVID EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.